以HIV-1 Vif与人APOBEC3G为靶点的抗HIV-1药物的研究方法  

Research methods of antiHIV-1 inhibitors targeting at Vif-APOBEC3G axis

作　　者：乔新华[1] 张文俊[1] 李泽琳[1] 曾毅[1] 

机构地区：[1]北京工业大学生命学院,北京100124

出　　处：《中国中药杂志》2011年第6期806-809,共4页China Journal of Chinese Materia Medica

基　　金：国家重点基础研究发展计划(973)项目(2009CB930203)

摘　　要：人载脂蛋白B mRNA编辑酶催化多肽样蛋白3G(apolipoprotein B mRNA-editing enzyme catalytic polypeptide 3protein G,APOBEC3G)是宿主的抗HIV-1(human immunodeficiency virus type 1)因子,而HIV-1辅助蛋白———病毒感染因子Vif(viral infectivity factor)可通过介导蛋白酶体途径降解APOBEC3G,因此针对APOBEC3G及HIV-1Vif进行抑制剂设计已经成为抗HIV-1药物研究新的方向之一,相应用于研究Vif-APOBEC3G相互作用的方法也越来越多,如免疫印迹、免疫杂交、脉冲追踪试验、生物发光共振能量转移检测、BIAcore检测等。作者将目前用于以Vif-APOBEC3G为靶点的药物的筛选及作用机制的研究方法进行了综述,为基于此的研究提供了策略。The mammalian APOBEC3G protein（apolipoprotein B mRNA-editing enzyme catalytic polypeptide 3 protein G,APOBEC3G） is an important component of the cellular innate immune response to retroviral infection.APOBEC3G can extinguish HIV-1（human immunodeficiency virus type 1） infectivity by its incorporation into virus particles and subsequent cytosine deaminase activity to block replication of HIV-1.HIV-1 Vif（viral infectivity factor）suppresses various APOBEC3 proteins through a common mechanism which induces the degradation of target proteins.Therefore,the interrelation of Vif-APOBEC3G has been extensively studied,which represents attractive targets for the development of novel inhibitors.We summarize the papers in which the detection technique and methords have been developed to assay the anti-HIV activity and its mechanism,such as western-blotting,co-immunoprecipitation,pulse-chase experiments,bioluminescence resonance energy transfer,biomolecular interaction analysis.This review is towards developing therapeutics aimed at the Vif-APOBEC3G axis.

关 键 词：APOBEC3G HIV-1Vif 抗HIV-1抑制剂 

分 类 号：R285[医药卫生—中药学]